ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma

Q. N. Yu, Y. B. Guo, X. Li, C. L. Li, W. P. Tan, X. L. Fan, Z. L. Qin, D. Chen, W. P. Wen, S. G. Zheng, Q. L. Fu

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Background: Group 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. Methods: The asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3 months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated in vitro. Results: The patients were well-controlled, and the high ILC2 levels were significantly decreased at 1 and 3 months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL-5, IL-13 and IL-9 in response to IL-25, IL-33 plus IL-2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL-5, IL-13 and IL-9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. Conclusion: The data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK-STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.

LanguageEnglish (US)
Pages1860-1870
Number of pages11
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume73
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Glucocorticoids
Asthma
Interleukin-9
Therapeutics
Interleukin-13
Interleukin-5
Mitogen-Activated Protein Kinase Kinases
Nuclear Family
Interleukin-2
Monocytes
Hypersensitivity
Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Yu, Q. N. ; Guo, Y. B. ; Li, X. ; Li, C. L. ; Tan, W. P. ; Fan, X. L. ; Qin, Z. L. ; Chen, D. ; Wen, W. P. ; Zheng, S. G. ; Fu, Q. L./ ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. In: Allergy: European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 9. pp. 1860-1870
@article{0e6e7c3da3eb49f699a66d30c5831b0d,
title = "ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma",
abstract = "Background: Group 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. Methods: The asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3 months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated in vitro. Results: The patients were well-controlled, and the high ILC2 levels were significantly decreased at 1 and 3 months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL-5, IL-13 and IL-9 in response to IL-25, IL-33 plus IL-2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL-5, IL-13 and IL-9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. Conclusion: The data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK-STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.",
author = "Yu, {Q. N.} and Guo, {Y. B.} and X. Li and Li, {C. L.} and Tan, {W. P.} and Fan, {X. L.} and Qin, {Z. L.} and D. Chen and Wen, {W. P.} and Zheng, {S. G.} and Fu, {Q. L.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/all.13438",
language = "English (US)",
volume = "73",
pages = "1860--1870",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "9",

}

Yu, QN, Guo, YB, Li, X, Li, CL, Tan, WP, Fan, XL, Qin, ZL, Chen, D, Wen, WP, Zheng, SG & Fu, QL 2018, 'ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma' Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 9, pp. 1860-1870. DOI: 10.1111/all.13438

ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. / Yu, Q. N.; Guo, Y. B.; Li, X.; Li, C. L.; Tan, W. P.; Fan, X. L.; Qin, Z. L.; Chen, D.; Wen, W. P.; Zheng, S. G.; Fu, Q. L.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 9, 01.09.2018, p. 1860-1870.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma

AU - Yu,Q. N.

AU - Guo,Y. B.

AU - Li,X.

AU - Li,C. L.

AU - Tan,W. P.

AU - Fan,X. L.

AU - Qin,Z. L.

AU - Chen,D.

AU - Wen,W. P.

AU - Zheng,S. G.

AU - Fu,Q. L.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Group 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. Methods: The asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3 months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated in vitro. Results: The patients were well-controlled, and the high ILC2 levels were significantly decreased at 1 and 3 months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL-5, IL-13 and IL-9 in response to IL-25, IL-33 plus IL-2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL-5, IL-13 and IL-9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. Conclusion: The data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK-STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.

AB - Background: Group 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. Methods: The asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3 months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated in vitro. Results: The patients were well-controlled, and the high ILC2 levels were significantly decreased at 1 and 3 months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL-5, IL-13 and IL-9 in response to IL-25, IL-33 plus IL-2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL-5, IL-13 and IL-9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. Conclusion: The data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK-STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.

UR - http://www.scopus.com/inward/record.url?scp=85049120960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049120960&partnerID=8YFLogxK

U2 - 10.1111/all.13438

DO - 10.1111/all.13438

M3 - Article

VL - 73

SP - 1860

EP - 1870

JO - Allergy: European Journal of Allergy and Clinical Immunology

T2 - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -